Are Medical Stocks Lagging Atea Pharmaceuticals (AVIR) This Year? [Yahoo! Finance]
Atea Pharmaceuticals, Inc. - common stock (AVIR)
US:NASDAQ Investor Relations:
investors.aviragentherapeutics.com/news-releases/news-release-details/aviragen-therapeutics-and-vaxart-enter-merger-agreement
Company Research
Source: Yahoo! Finance
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Atea Pharmaceuticals, Inc. (AVIR) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question. Atea Pharmaceuticals, Inc. is one of 1025 companies in the Medical group. The Medical group currently sits at #2 within the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market o
Show less
Read more
Impact Snapshot
Event Time:
AVIR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AVIR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AVIR alerts
High impacting Atea Pharmaceuticals, Inc. - common stock news events
Weekly update
A roundup of the hottest topics
AVIR
News
- Atea Pharmaceuticals to Host Third Quarter 2024 Financial Results Conference Call on November 7, 2024GlobeNewswire
- Atea Pharmaceuticals to Present New Data Supporting the Combination of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at AASLD’s The Liver Meeting 2024GlobeNewswire
- Atea Pharmaceuticals' COVID-19 Treatment Flunks In Late-Stage Study, Blames 'Constantly Evolving' Virus [Yahoo! Finance]Yahoo! Finance
- Atea Pharmaceuticals Provides Update on Global Phase 3 SUNRISE-3 Trial Evaluating Bemnifosbuvir for Treatment of COVID-19GlobeNewswire
- Atea Pharmaceuticals, Inc. (NASDAQ: AVIR) was upgraded by analysts at William Blair to a "strong-buy" rating.MarketBeat
AVIR
Earnings
- 8/7/24 - Beat
AVIR
Sec Filings
- 9/19/24 - Form 4
- 9/19/24 - Form 144
- 9/18/24 - Form 144
- AVIR's page on the SEC website